Latest Prime Therapeutics Stories
DuCharme served as Prime's CFO since 2012 ST.
Prime Therapeutics study finds combination treatment targeting gene mutations could add approximately $150 million per year in new costs ST.
A new drug, increasing use, extreme costs highlight need for integrated claims data to better identify people with the disorder, develop clinical programs that improve care, reduce costs
In the wake of the Food and Drug Administration’s first approval for a biosimilar product, pharma industry experts offer advice on how payers can prepare for this new class of drugs in the March
Findings show 13.6% higher medication usage, 16.4% higher spend on specialty medications ST.
New research finds only biosimilars for blockbuster biologics are likely viable ST. PAUL, Minn., Feb.
Analysis identifies opportunities to help reduce controlled substance abuse and lower costs ST. PAUL, Minn., Feb.
Agreements support both treatment therapies while helping members, health plans and employers manage costs ST. PAUL, Minn., Jan.
- Growing in low tufty patches.